Drug Trial Radar · NCT07275736
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Mar 1, 2025
Primary completion
Jun 1, 2027
Study completion Jun 1, 2029
Sponsor
- Lead sponsor
- Juventas Cell Therapy Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Beijing Tiantan Hospital
- First posted
- Dec 10, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of CNCT19 cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases.
Conditions
- Neurological Autoimmune Diseases
Interventions
CNCT19 cell injectionBiological
A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose-limiting toxicities (DLTs)Time frame: Up to 28 days after infusion
- Number of participants with adverse events (AEs)/serious adverse events (SAEs)Time frame: up to Month 36
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.